inVentiv Health has extended its partnership with the Swedish biotech NeuroVive Pharmaceutical.
The new deal will see consultancy firm InVentiv assist NeuroVive with the global commercialisation of its lead product, CicloMulsion, which is currently in phase III trials to determine its effectiveness in reducing cardiac damage following stenting in heart attack patients.
The partnership builds on a one-year regulatory consulting collaboration between NeuroVive and ParagonRx, inVentiv’s risk mitigation service.
Dan Feldman, President of inVentiv Health Europe, said: “We’re big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialise their compound, and we’re flexible enough to align with whatever they need to achieve their objectives.”
He added: “Pharmaceutical companies face a far more challenging market environment than ever before. Today’s market requires innovative strategic partnerships. inVentiv Health was created to provide this new model for the new marketplace.”
inVentiv will provide NeuroVive with market assessment services through its consulting arm, Campbell Alliance, which specialises in helping companies sell more effectively in an environment increasingly dominated by third-party payers.
NeuroVive and inVentiv are already discussing a broader expansion of the partnership to include future development and commercialisation services for CicloMulsion.
”We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion in Europe and, later, in the US,” said NeuroVive CEO Mikael Brönnegård.
“inVentiv Health´s commercial services will provide a valuable platform for optimal market penetration at later stages and when approaching the launch and marketing of the product,” he added.